Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
Top Cited Papers
- 1 June 2007
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 109 (11), 4648-4654
- https://doi.org/10.1182/blood-2006-11-056291
Abstract
The CANAL Study (Concerted Action on Neutralizing Antibodies in severe hemophilia A) was designed to describe the relationship between treatment characteristics and inhibitor development in previously untreated patients with severe hemophilia A. This multicenter retrospective cohort study investigated 366 consecutive patients born between 1990 and 2000. The outcome was clinically relevant inhibitor development, defined as the occurrence of at least 2 positive inhibitor titers combined with a decreased recovery. Eighty-seven (24%) patients developed inhibitors (69 high titer [19%]). The incidence of inhibitors appeared to be associated with age at first treatment, decreasing from 41% for those treated within the first month of age to 18% in those treated after 18 months; after adjustment for treatment intensity, this association largely disappeared. Surgical procedures and peak treatment moments at start of treatment increased inhibitor risk (relative risk [RR], 3.7; 95% confidence interval [CI], 2.0-7.1; and RR, 3.3; CI, 2.1-5.3, respectively). Regular prophylaxis was associated with a 60% lower risk than on-demand treatment (RR, 0.4; CI, 0.2-0.8). Our findings suggest that the previously reported associated between an early age at first exposure and the risk of inhibitor development is largely explained by early, intensive treatment. The latter appears to be an independent risk factor for inhibitor development. In addition, early, regular prophylaxis may protect patients with hemophilia against the development of inhibitors.Keywords
This publication has 37 references indexed in Scilit:
- Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required.British Journal of Haematology, 2006
- Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Response to Calvez and LaurianBritish Journal of Haematology, 2006
- Prophylactic treatment effects on inhibitor risk: experience in one centreHaemophilia, 2005
- NO PROTECTIVE EFFECT OF BREASTFEEDING ON INHIBITOR FORMATION IN SEVERE HEMOPHILIAPediatric Hematology and Oncology, 2005
- Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia AThrombosis and Haemostasis, 2005
- Haemophilia in the developing world: successes, frustrations and opportunitiesHaemophilia, 2004
- The Danger Model: A Renewed Sense of SelfScience, 2002
- The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor developmentHaemophilia, 2001
- Relation of pooled logistic regression to time dependent cox regression analysis: The framingham heart studyStatistics in Medicine, 1990
- Genetic predisposition to develop factor VIII antibody in classic hemophiliaClinical Immunology and Immunopathology, 1977